secwatch / observer
8-K filed March 2, 2026, 6:59 PM ET ticker GYRE CIK 0001124105
M&A confidence high sentiment positive materiality 0.85

Gyre acquires Cullgen for ~$300M in stock; gains TPD/DAC platform, new CEO appointed

GYRE THERAPEUTICS, INC.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

GYRE THERAPEUTICS, INC.: Gyre Therapeutics expects to file a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock in connection with a merger, creating a new class of preferred stock with specific dividend, voting, conversion, and anti-takeover provisions (effective 2026-03-02).

Change
charter amendment
Effective
2026-03-02
Exact text from the filing
The Company expects to file with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock (the "Certificate of Designation") in connection with the Merger referenced in Item 1.01 above.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GYRE THERAPEUTICS, INC. entered into Support Agreements with Cullgen, Inc. and certain stockholders valued at Undisclosed (effective 2026-03-02).

Action
entry
Agreement
merger
Counterparty
Cullgen, Inc. and certain stockholders
Value
Undisclosed
Effective
2026-03-02
Exact text from the filing
Concurrently with the execution of the Merger Agreement, (i) certain officers, directors, and stockholders of the Company (solely in their respective capacities as Company stockholders) have entered into support agreements with the Company and Cullgen to vote all of their shares of Company Common Stock in favor of the Conversion Proposal (the “Company Support Agreement”), and (ii) certain officers, directors and stockholders of Cullgen (solely in their respective capacities as Cullgen stockholders) have entered into support agreements with the Company and Cullgen to vote all of their shares of Cullgen Capital Stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals (the “ Cullgen Support Agreement” and together with the Company Support Agreement, the “ Support Agreements”).
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GYRE THERAPEUTICS, INC. entered into Registration Rights Agreement with Cullgen, Inc. and certain holders of Cullgen Capital Stock valued at Undisclosed.

Action
entry
Counterparty
Cullgen, Inc. and certain holders of Cullgen Capital Stock
Value
Undisclosed
Exact text from the filing
In connection with the closing of the Merger, the Company will enter into a Registration Rights Agreement (the “Registration Rights Agreement”) with Cullgen and certain holders of shares of Cullgen Capital Stock signatory thereto (the “Company Holders”).
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GYRE THERAPEUTICS, INC. entered into Lock-Up Agreements with Certain executive officers, directors and stockholders of Company and Cullgen valued at Undisclosed (effective 2026-03-02).

Action
entry
Agreement
merger
Counterparty
Certain executive officers, directors and stockholders of Company and Cullgen
Value
Undisclosed
Effective
2026-03-02
Exact text from the filing
Concurrently with the execution of the Merger Agreement, certain executive officers, directors and stockholders of the Company and Cullgen have entered into lock-up agreements (the “Lock-Up Agreements”) pursuant to which, subject to specified exceptions, they have agreed not to transfer their shares of Company Common Stock (or shares convertible for Company Common Stock) for (a) with respect to one-third of the shares of Company Common Stock held by them, the 180-day period following the Merger Closing Date, (b) with respect to one-third of the shares of Company Common Stock held by them, the twelve-month period following the Merger Closing Date, and (c) with respect to one-third of the shares of Company Common Stock held by them, the eighteen month period following the Merger Closing Date.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GYRE THERAPEUTICS, INC. entered into Merger Agreement with Cullgen, Inc. valued at Undisclosed (effective 2026-03-02).

Action
entry
Agreement
merger
Counterparty
Cullgen, Inc.
Value
Undisclosed
Effective
2026-03-02
Exact text from the filing
Each of the Company and Cullgen has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1) using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2) non-solicitation of alternative acquisition proposals, (3) the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, and (4) the Company filing with the U.S. Securities and Exchange Commission (the “SEC”) a proxy statement and other relevant materials relating to the Conversion Proposal (as defined below).
View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR
accession 0001140361-26-007249
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.